Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon γ: Immunological monitoring

We investigated the biological response of 73 patients with metastatic renal-cell carcinoma (MRCC) treated by repetitive weekly cycles of high-dose interleukin 2 (IL-2) (protocol 1, 40 patients) or IL-2 plus interferon-gamma (IFN-γ) (protocol 2, 33 patients). The objectives of this study were (i) to evaluate the effects of this IL-2 administration schedule on biological response, (ii) to compare the effects of IL-2 alone with those of IL-2 plus IFN-γ, (iii) to search for any correlation between certain biological marker values and the clinical response to treatment. Mean CD56⁺ lymphocyte counts (i. e., NK cells) were significantly higher than those of CD3⁺ cells in the 2 protocols and a subpopulation of CD56^bright cells in protocol I was found to be preferentially expanded in vivo. Cytotoxic activity against K562 and Daudi cell lines as well as TNF-α and sTNF-αR (but not IL-6) significantly increased following treatment. Comparison of the data obtained from patients treated with IL-2 alone vs. IL-2 plus IFN-γ did not show any significant changes except for eosinophilia (higher in protocol I). Therefore, addition of IFN-γ did not affect either lymphocyte distribution or non-MHC-restricted cytotoxicity in vivo. No difference in cell subpopulation or cytotoxicity was detected between responders and non-responders. Pre-treatment sTNF-αR concentration, in contrast to IL-6 and TNF-α, was significantly higher in progressive than in stable and responder groups, suggesting that this parameter may be predictive of the clinical response. © 1994 Wiley-Liss, Inc.